Best Infectious Diseases Companies in San Diego, United States

Developer of sexual and reproductive health therapeutics. It offers two drug products which include PHEXXI vaginal gel that provides women with an in-the-moment contraceptive that maintains the baseline vaginal pH environment and SOLOSEC (secnidazole) which is used to treat bacterial vaginosis in women and the STI trichomoniasis in both men and women.

Funding rounds

• Jun 2025Post IPO$925K
• Apr 2025Post IPO$750K
• Sep 2023Post IPO$2.9M
• Feb 2023Post IPO$1.4M

Founders & team

Saundra PelletierCEO ► Phexxi ► Solosec

Investors

Woodford Investment Management, Invesco Mutual Fund, Adjuvant Capital, Keystone Capital, Walleye, Pinz Capital Management

Glycoscience company developing heparan sulfate therapies and enzyme replacement therapy. Specializing in glycans, the company focuses on exploiting glycoscience-related technologies for treating life-threatening diseases. The company's pipeline includes recombinant production of heparan sulfate and enzyme replacement therapy to address genetic deficiencies in heparan sulfate degradation. They are dedicated to advancing the understanding and application of complex carbohydrates in medicine, aiming to unlock the therapeutic potential of glycans. This innovative approach positions them at the forefront of glycoscience, offering hope for novel treatments in areas with unmet medical needs.

Developer of novel anti-infectives for infectious diseases (bacterial and fungal). Its first product candidate is CD101 IV, an intravenous therapy in phase 1 trials for fungal infections. Besides, it has CD101 topical in the IND-enabling stage for the treatment of acute and recurrent vulvovaginal candidiasis (VVS). It has also developed a proprietary immunotherapy technology platform, Cloudbreak to develop drugs that direct immune cells to eliminate pathogens that cause infectious diseases. Its first Cloudbreak development candidate C001 is for the treatment of invasive aspergillosis.

Funding rounds

• Nov 2024Post IPO$105M
• Apr 2024Post IPO$240M
• Sep 2019Post IPO$9M
• May 2018Post IPO$1.6M

Founders & team

Jeff SteinCEO

Investors

Great Point Partners, BB Biotech, Broadfin Capital, Investopedia, Venrock, RA Capital Management

Tech stack

WordpressMysqlPhpMaterial Design LiteWpbakeryYoast Seo

Okogen is developing ophthalmic anti-viral drugs. The lead candidate, OKG-0301 is a broad spectrum antiviral drug that inhibits viral replication. This molecule is a ribonuclease targets degradation of tRNA and miRNA which causes protein synthesis inhibition. The company is targeting this molecule for adenoviral conjunctivitis & also planning to test it against CMV retinitis and exotic viral infections. In Feb 2017, The company got $10 million in Series A funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) to develop OKG-0301 for viral conjunctivitis.

Funding rounds

• Nov 2024Series A$2.5M
• Dec 2023Series A$213K
• Feb 2018Series A$10M
• Dec 2017Series A$6.2M

Founders & team

Eric DanielsFounder & COOBrian StremCEO

Investors

Brandon Capital

Tech stack

WordpressMysqlPhpHello ElementorWp RocketUltimate Addons For Elementor

Developer of AAV-based gene therapies to treat genetically defined muscle disease

Immunotherapeutic device company combating cancer and life-threatening viral infections. It is focused on developing a first-in-class technology for the rapid depletion of cancer-promoting exosomes and circulating viruses. Their device is designated as a breakthrough technology for treating individuals with advanced or metastatic cancer unresponsive to standard therapies, particularly in cancer types where exosomes contribute to disease development. The device also targets life-threatening viruses lacking approved treatments. The company aims to augment the body's natural immune defenses through its innovative approach to blood purification. This is a medical device company.

Funding rounds

• Dec 2025Post IPO$2.2M
• Aug 2020Grant (prize money)$3.5M
• Sep 2018Grant (prize money)$298.4K
• Jul 2015Post IPO$6M

Founders & team

Charles FisherCEO

Investors

NIH, HHS

Tech stack

Apache Http ServerBootstrapFancyboxGoogle AnalyticsHcaptchaHsts

Developer of anti-viral therapies for respiratory viruses. The 2 lead candidates, Fludase and Paradase contain DAS-181. DAS181 is a bifunctional fusion protein comprised of a sialidase linked to a polycationic sequence derived from human amphiregulin (hAR) that allows the molecule to target the sialidase enzymatic activity to glycosaminoglycans (GAGs).

Developing novel solutions for neglected and emerging infectious diseases. The company is dedicated to the discovery and development of innovative therapeutic programs to combat these global health challenges. They focus on research and development to create effective treatments for infectious diseases. The company aims to address unmet medical needs through scientific advancements. Their work has a significant social impact, contributing to public health and disease prevention. They are committed to advancing medical science and improving patient outcomes in the field of infectious disease. The company fosters innovation and collaboration to accelerate the development of new therapies.

Pharmaceutical company focused on innovative medicines, vaccines, and expanded access programs. It researches, develops, manufactures, and markets healthcare products. The company is dedicated to advancing health equity and addressing unmet medical needs through scientific innovation. It offers expanded access programs, also known as compassionate use, for patients with serious illnesses who have exhausted other treatment options. The company conducts clinical trials to evaluate the safety and effectiveness of its products, and is committed to transparency and data integrity. It focuses on areas such as internal medicine, inflammation & immunology, vaccines, and oncology. The company also emphasizes responsible business practices, environmental sustainability, and ethical conduct. It partners with patients, healthcare professionals, and other organizations to improve global health outcomes.

Funding rounds

• Jan 2020Series C$91.3M
• Aug 2017Grant (prize money)$1.5M
• Jul 2016Grant (prize money)$1.5M
• Feb 2016Series B$8.7M

Founders & team

Mike GreyCEO

Investors

Tech Coast Angels, Life Science Angels, 3x5 Partners, Keiretsu Forum Seattle, Golden Seeds, Sofinnova Investments

PaxVax develops and commercializes vaccine candidates against various infectious diseases. Its products include PXVX0200, a single-dose oral vaccine against cholera; PXVX0103, an oral adenoviral-based vaccine against avian influenza (H5N1) or bird flu; a single-dose oral vaccine candidate for protection against anthrax; Ad4-env Clade C, a HIV vaccine component that expresses an optimized HIV envelope protein derived from a Clade C HIV strain, and commercializing Vivotif, a live typhoid fever vaccine for oral administration.

Innovating critical care and infectious disease therapies for global health. This biotechnology company develops and delivers innovative therapies for patients in critical care and infectious diseases, addressing urgent needs in areas of high unmet need. It focuses on combating serious conditions and advancing treatment options for life-threatening conditions and emerging illnesses caused by drug-resistant microorganisms. With a global mission, it advances solutions for critical and urgent infections identified by leading public health organizations. The company's therapies include new and established standards for critical care and infectious disease treatments. It is dedicated to delivering products that help save lives, blending rigorous medical science with pharmaceutical innovation. The company is building a culture where colleagues can make a lasting impact.

Provider of point-of-care molecular diagnostic kits. The palm-sized, reusable dock and disposable test cassette form a user-friendly system for use anywhere, from the physician’s office to the patient’s home. Proprietary assay design allows for the rapid development of a portfolio of tests for human, agricultural, food pathogens, or genetic disease targets. The flexibility of Mesa Biotech’s hardware design allows for rapid, sensitive, specific, multiplexed detection of disease targets in one easy-to-use device. Mesa Biotech’s technology thus offers the simplicity, convenience, and procedural familiarity of traditional POC rapid immunoassays while providing the superior sensitivity, specificity, and information content of laboratory-based molecular testing.